Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02124850
Title A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With ERBITUX® (Cetuximab) and VTX-2337
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors VentiRx Pharmaceuticals Inc.
Indications

oropharynx cancer

oral cavity cancer

head and neck squamous cell carcinoma

hypopharynx cancer

larynx cancer

Therapies

Cetuximab

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15232 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field